Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Image 3-Enspryng™ (satralizumab-mwge).jpg
The FDA approval for Enspryng is based on the results from the two 96-week clinical trials, the SAkuraStar and SAkuraSky. Credit: Business Wire.